Acontece no mês de fevereiro, no Parque de Exposições, em Patrocínio, o tradicional Rebanhão. O retiro será realizado durante o período do Carnaval, entre os dias 14 e 17 de fevereiro de 2026, ...
CARAS Brasil on MSN
Aos 29 anos, com vitória em reality, novo nome e casada, cantora vive longe do gospel
Depois de crescer na TV e lançar sucessos no gospel, cantora escolheu um caminho diferente na música aos 29 anos ...
participação do Coral Municipal Cultural de Pareci Novo na Vindima de Vila Flores em 2026 revela excelência musical e ...
Novo Nordisk’s (NYSE: NVO) Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x story moving forward, provided it effectively ...
A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. The starting dose ...
Shortly after scoring a historic FDA nod for its Wegovy pill, Novo Nordisk is off to the races with the oral obesity med’s launch. The once-daily pill officially debuted in the U.S. Monday, with the ...
The Wegovy pill is the first and only oral GLP-1 for weight loss in adults. The first and only oral GLP-1 for weight loss in adults is now available to consumers. Drugmaker Novo Nordisk announced ...
As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers. Spherix Global Insights ...
When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...
Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026. Novo ...
Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk’s acquisition of Akero, ...
Novo Nordisk remains a Strong Buy despite recent earnings misses, trial setbacks, and competitive pressures in the weight loss/diabetes market. NVO's valuation is compelling, trading at a low P/E of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results